Global Growth Factors (Blood and Tissue) Market to Reach $101.5 Billion by 2030
The global market for Growth Factors (Blood and Tissue) estimated at US$40.3 Billion in the year 2022, is projected to reach a revised size of US$101.5 Billion by 2030, growing at a CAGR of 12.2% over the analysis period 2022-2030. Interferons, one of the segments analyzed in the report, is projected to record 15.1% CAGR and reach US$78.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Colony Stimulating Factors segment is readjusted to a revised -0.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $11 Billion, While China is Forecast to Grow at 18.4% CAGR
The Growth Factors (Blood and Tissue) market in the U.S. is estimated at US$11 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$26.2 Billion by the year 2030 trailing a CAGR of 18.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 11.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.Select Competitors (Total 101 Featured) -
- Amgen, Inc.
- Bayer HealthCare Pharmaceuticals, Inc.
- Biocon Ltd.
- Biogen, Inc.
- Biopharm GmbH
- Bolder BioTechnology, Inc.
- Chugai Pharmaceutical Co. Ltd.
- F. Hoffmann-La Roche AG
- FibroGen, Inc.
- Genentech, Inc.
- Janssen Biotech, Inc.
- Johnson & Johnson
- Lonza Group
- Merck Serono
- PeproTech, Inc.
- Reliance GeneMedix Plc
- Sangamo Therapeutics, Inc.
- Sanofi
- Scil Proteins GmbH
- Teva Pharmaceutical Industries Ltd.
- Wockhardt Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Growth Factors (Blood and Tissue) - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- An Introduction to Growth Factors
- Interferons
- Colony Stimulating Factors
- Erythropoietins
- Interleukins
- Global Market Prospects & Outlook
- Recent Market Activity
3. MARKET TRENDS & DRIVERS
- Growing Adoption of Growth Factors in Pharmaceutical & Biotech Companies
- Global Spending on Pharmaceuticals (in US$ Billion)
- Life Science Research and Clinical Trials for Novel Drug Development and Therapies to Boost Market
- Cell Culture-based Research Fuels Need for Growth Factors
- Global Cell Culture Market Size (in US$ Billion) for the Years 2020, 2022 and 2025
- Expanding Stem Cell Biology Applications & Focus on Stem Cell Research Initiatives Spur Demand for Growth Factors
- Rising Use of Growth Factors in Regenerative Medicines and Tissue Regeneration
- Global Regenerative Medicine Market Size (US$ Billion) for 2020, 2022 & 2025
- Global Tissue Engineering Market Size (US$ Billion) for 2020, 2022 & 2025
- Increasing Funding for Life Science Research Underpinning Gains
- Funding in Life Sciences industry: Number of Deals for 2010 to 2020
- Global Funding Rounds ($100 Million+) in Life Science-Related Sectors: 2016-2020
- Growth Factors Find Increasing Role in Wound Healing and Skin Regeneration
- Oncology Research Focus Drives Importance of Growth Factors
- Erythropoietin (EPO) Market: Potential Opportunities from Anemia in CKD and Cancer Patients
- Interferons Market to Benefit from Rising Demand for Specialized Therapies
- Growing Importance of Interferons in Viral Infections
- Colony Stimulating Factors (CSFs) Market
- Interleukins Market: Applications to Drive Market Growth
- Neurotrophic Therapeutics: Opportunities in Store
- Blood Growth Factors Market
- Role of Growth Factors in Multiple Sclerosis Drugs
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Interleukins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 18: World 16-Year Perspective for Other Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 19: World Growth Factors (Blood and Tissue) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 20: USA Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 21: USA Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: USA 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
CANADA
- Table 23: Canada Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 24: Canada Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: Canada 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
JAPAN
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 26: Japan Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: Japan Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: Japan 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
CHINA
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 29: China Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: China Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: China 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
EUROPE
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 32: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 33: Europe Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 35: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
FRANCE
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 38: France Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: France Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: France 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
GERMANY
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 41: Germany Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Germany Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Germany 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
ITALY
- Table 44: Italy Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Italy Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Italy 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 47: UK Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: UK Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: UK 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
SPAIN
- Table 50: Spain Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Spain Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Spain 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
RUSSIA
- Table 53: Russia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: Russia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Russia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
REST OF EUROPE
- Table 56: Rest of Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Rest of Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Rest of Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 60: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
AUSTRALIA
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen, Inc.
- Bayer HealthCare Pharmaceuticals, Inc.
- Biocon Ltd.
- Biogen, Inc.
- Biopharm GmbH
- Bolder BioTechnology, Inc.
- Chugai Pharmaceutical Co. Ltd.
- F. Hoffmann-La Roche AG
- FibroGen, Inc.
- Genentech, Inc.
- Janssen Biotech, Inc.
- Johnson & Johnson
- Lonza Group
- Merck Serono
- PeproTech, Inc.
- Reliance GeneMedix Plc
- Sangamo Therapeutics, Inc.
- Sanofi
- Scil Proteins GmbH
- Teva Pharmaceutical Industries Ltd.
- Wockhardt Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 223 |
| Published | April 2024 |
| Forecast Period | 2020 - 2027 |
| Estimated Market Value ( USD | $ 40.8 Billion |
| Forecasted Market Value ( USD | $ 74.1 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
